Author

D. Araiza-Olivera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:statistical model· 1

Frequent Co-Authors

A. M. Kurimchak· 2 shared C. Uribe-Alvarez· 2 shared J. Chernoff· 2 shared J. S. Duncan· 2 shared A. C. Cannon· 1 shared A. Cannon· 1 shared C. Herrera-Montavez· 1 shared J. Hu· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. M. Kurimchak

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 27, 2023

Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints

A. C. Cannon, K. Budagyan, C. Uribe-Alvarez…·J. Chernoff

This study identifies CDK9 as a novel therapeutic target in RAC1P29S-mutant melanoma and shows that combining CDK9 inhibition with anti-PD-1 therapy enhances tumor suppression.

DOI 10.1101/2023.06.27.546707

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivDec 2, 2021

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

A. M. Kurimchak, C. Herrera-Montavez, S. Montserrat-Sangra…·J. S. Duncan

This study identifies MDR1 as a mediator of resistance to PROTACs in cancer cells and shows that combining MDR1 inhibitors with PROTACs enhances drug efficacy.

DOI 10.1126/scisignal.abn2707

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivAug 28, 2019

Targeting effector pathways in RAC1P29S-driven malignant melanoma

C. Uribe-Alvarez, S. L. Guerrero-Rodriguez, J. Rhodes…·D. Araiza-Olivera

This study investigates the efficacy of targeting effector pathways of RAC1P29S in melanoma, showing that PAK and SRF/MRTF inhibitors reduce tumor growth in vitro and in zebrafish models.

DOI 10.1080/21541248.2020.1728469

zebrafishproteomics

𝕏 PostBluesky